<DOC>
	<DOC>NCT01996033</DOC>
	<brief_summary>The purpose of this observational study is to further evaluate the safety and performance of the EnligHTN™ Renal Denervation System in the treatment of patients with uncontrolled hypertension in clinical routine practice.</brief_summary>
	<brief_title>EnligHTN German Observational Study of Renal Denervation for Uncontrolled Hypertension</brief_title>
	<detailed_description>This is a post market, multi-center, open label, observational study. Approximately 500 subjects with uncontrolled hypertension will undergo renal artery ablation at approximately 40 investigational sites located in Germany and will be followed for 1 year post procedure.The expected duration of the investigation will be approximately 4 years.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Subject is planned to undergo a renal denervation procedure for the treatment of hypertension Subject is ≥18 years of age at time of consent Subject must be able and willing to provide written informed consent Subject must be able and willing to comply with the required followup schedule Subject has office Systolic Blood Pressure (SBP) ≥ 140 mmHg Subject has established hypertension (diagnosed ≥12 months prior to baseline) and is on a guideline based drug regimen at a stable (≥ 14 days) and a fully tolerated dose consisting of ≥3 antihypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of antihypertensives (ACEI/ Angiotensin Receptor Blocker (ARB), Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 antihypertensive drugs Subject has known significant renovascular abnormalities such as renal artery stenosis &gt; 30% Subject has undergone prior renal angioplasty, renal denervation, indwelling renal stents, and/or abdominal aortic stent grafts Subject has a history of hemodynamically significant valvular heart disease Subject has blood clotting abnormalities Subject life expectancy is &lt; 12 months, as determined by the Study Investigator Subject is participating in another clinical study which has the potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>uncontrolled hypertension</keyword>
	<keyword>Renal Denervation</keyword>
</DOC>